Reports

• CIPARS Annual Reports
• Preliminary Results
• Quarterly Summaries
• Additional Information

Annual Reports

• 2007 CIPARS Report
  
• 2006 CIPARS Report
• 2005 CIPARS Report
• 2004 CIPARS Report
• 2003 CIPARS Report
• 2002 CIPARS Report

Preliminary Results

• 2009 Preliminary Results
• 2008 Preliminary Results
  • 2008 Farm Surveillance Preliminary Results
• 2007 Preliminary Results
  • 2007 Farm Surveillance Preliminary Results
• 2006 Preliminary Results
• 2005 Preliminary Results

Quarterly Summaries

Salmonella in Agri-food

• Q1 2010: January to March 2010
• Q2 2010: April to June 2010
• Q3 2010: July - September 2010

Additional Information

• Recovery rate and final number of isolates submitted for antimicrobial resistance (AMR) testing across the bacterial species, the active surveillance components and the animal species, 2002-2005
• Salmonella Heidelberg – Ceftiofur-Related Resistance in Human and Retail Chicken Isolates 2003-2006
  • Update Salmonella Heidelberg Ceftiofur-Related Resistance in Human and Retail Chicken Isolates - 2006 to 2008 (March 2009)
• Oral Macrolide Consumption in Canadian Provinces from 2000-2006

CIPARS Reporting

CIPARS generates an annual report summarizing the main antimicrobial resistance findings from all of CIPARS components.  The annual report also integrates information related to human consumption of antimicrobials.  In an effort to deliver the information in a timely fashion, CIPARS now posts an annual preliminary report containing antimicrobial results available at the time of analysis.  CIPARS also posts web-based ad-hoc reports highlighting issues on antimicrobial resistance and/or antimicrobial consumption. 

CIPARS provides prevalence of antimicrobial resistance to individual antimicrobials; information related to antimicrobial resistance patterns and multiple drug resistance, and recovery rates for its active components and serotypes distribution.  Resistance results are presented according to the Health Canada Veterinary Drug Directorate classification of antimicrobial drugs based on their importance in human medicine.  Drug consumption data are interpreted in collaboration with the Canadian Committee on Antimicrobial Resistance (CCAR).  When appropriate, CIPARS integrates data from various sources in order to explore relationships between antimicrobial resistance in isolates from Canada's agri-food sector and human sectors.

CIPARS results are useful to a broad variety of stakeholders and end-users, including the Veterinary Drugs Directorate, and Food Directorate's Bureau of Microbial Hazards , and the Canadian Food Inspection Agency .  Drug use information has been useful to provincial groups as well.